T · 6090.T
Human Metabolome Technologies, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Tsuruoka 997-0052
- Website
- humanmetabolome.com
Price · as of 2025-06-30
$690.00
Market cap 3.96B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $568.84 | -17.56% |
| Intrinsic Value(DCF) | $670.00 | -2.9% |
| Graham-Dodd Method(GD) | $317.93 | -53.92% |
| Graham Formula(GF) | $696.37 | +0.92% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $1,063.72 | ||||
| 2021 | $734.38 | $620.11 | $196.69 | $262.96 | $84.05 |
| 2022 | $878.23 | $2,519.29 | $233.05 | $478.87 | $751.04 |
| 2023 | $701.93 | $505.12 | $278.70 | $541.98 | $680.45 |
| 2024 | $571.31 | $490.67 | $303.94 | $386.02 | $476.13 |
| 2025 | $740.00 | $568.84 | $438.00 | $317.93 | $696.37 |
AI valuation
Our deep-learning model estimates Human Metabolome Technologies, Inc.'s (6090.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $568.84
- Current price
- $690.00
- AI upside
- -17.56%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$670.00
-2.9% upside
Graham-Dodd
$317.93
-53.92% upside
Graham Formula
$696.37
+0.92% upside
About Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
- CEO
- Yasuhiro Ohata
- Employees
- 58
- Beta
- -0.14
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($670.00 ÷ $690.00) − 1 = -2.9% (DCF, example).